The FDA has approved a new freeze-dried formulation of Jynneos (smallpox and mpox vaccine, live, non-replicating).

A recent study carried out at Charité Universitätsmedizin Berlin and published in The Lancet Infectious Diseases has shown that one dose of Bavarian Nordic’s Jynneos (smallpox and mpox vaccine ...

Bavarian Nordic said it was contracted by the U.S Biomedical Advanced Research and Development Authority to develop and supply the freeze-dried version of Jynneos for stockpiling.

“Even in light of these promising data, we strongly recommend people receive two doses of Jynneos vaccine spaced out 28 days apart to ensure durable, lasting immune protection against monkeypox ...

Health officials are advising people at higher risk of mpox infection to consider being vaccinated with two doses of the JYNNEOS vaccine, which is available statewide. Laboratory testing of the ...

Also, their recently FDA-approved freeze-dried Jynneos vaccine and EU/US-approved chikungunya vaccine launches are near-term growth catalysts. BVNKF’s 2025 outlook also suggests they still have ...

According to the U.S. Centers for Disease Control and Prevention, ACAM2000 has more known side effects and risks than Danish biotech Bavarian Nordic A/S's Jynneos vaccine, which is approved in the ...

Marketed as Jynneos in the US, the vaccine currently exists in a liquid-frozen formulation. These products require a temperature-controlled supply chain that keeps them frozen between production ...

The company said the newly approved formulation of its vaccine, Jynneos, provides advantages in terms of transportation, storage conditions and shelf life, which are important factors for long ...

The company said the newly approved formulation of its vaccine, Jynneos, provides advantages in terms of transportation, storage conditions and shelf life, which are important factors for long-term ...